Analytical Data
-
Gene name
cpg2
- Application
-
Alternative Names
Folate hydrolase G2Glutamate carboxypeptidasePteroylmonoglutamic acid hydrolase G2INN: Glucarpidase
-
Species
Pseudomonas sp.
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P06621
-
Expression Region
23-415aa
-
Molecular Weight
68.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CPG2, a recombinant protein derived from the human cytoplasmic enzyme carboxypeptidase G2, has garnered significant interest in the field of biomedicine, particularly due to its potential applications in targeted cancer therapy and drug delivery systems. Unlike traditional modes of cytotoxicity, CPG2 functions as a targeted enzyme that catalyzes the hydrolysis of specific substrates, leading to selective tumor cell death when combined with prodrugs. Its unique mechanism allows for enhanced therapeutic effects while minimizing damage to surrounding healthy tissues. The study of CPG2 encompasses various aspects, including its enzymatic activity, structural biology, and interactions with other biomolecules. Researchers are exploring recombinant expression systems to produce high yields of this protein, optimizing its pharmacokinetics, and investigating its efficacy in preclinical models of cancer. Furthermore, the engineering of CPG2 to improve its specificity and stability presents a promising avenue for enhancing its therapeutic index in clinical settings. Overall, the exploration of CPG2 as a novel therapeutic agent positions it as a significant player in the advancement of targeted therapies, potentially improving treatment outcomes for patients with various malignancies.
